Phospho-TSC2 (S939) Antibody

What is Phospho-TSC2 (S939) Antibody and what specific epitope does it recognize?

Phospho-TSC2 (S939) Antibody is a research tool that specifically recognizes the TSC2 protein (also known as Tuberin) only when phosphorylated at the serine 939 position. This antibody is typically generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S939 of human TSC2 . The antibody is designed to bind specifically to this phosphorylation site and does not cross-react with non-phosphorylated TSC2 or other phosphorylation sites on the protein .

What is the biological significance of TSC2 phosphorylation at Ser939?

Phosphorylation of TSC2 at Ser939 plays a critical role in regulating the activity of the TSC-TBC complex. This complex acts as a negative regulator of the canonical mTORC1 pathway, which is an evolutionarily conserved nutrient sensor that controls anabolic reactions and macromolecule biosynthesis . Specifically, S939 phosphorylation by PKB/AKT1 in response to insulin signaling and growth factor stimulation inhibits the ability of the TSC-TBC complex to suppress mTORC1 signaling . Phosphorylation promotes dissociation of the TSC-TBC complex from lysosomal membranes, leading to activation of mTORC1 by RHEB . Additionally, S939 phosphorylation is critical for the cytosolic translocation of tuberin from cellular membranes, as demonstrated by mutation studies where S939A prevents this translocation .

How does TSC2 function within cellular signaling pathways?

TSC2 functions as the catalytic component of the TSC-TBC complex, which negatively regulates mTORC1 signaling. Within this complex, TSC2 acts as a GTPase-activating protein (GAP) for the small GTPase RHEB, a direct activator of the protein kinase activity of mTORC1 . In the absence of nutrients, the TSC-TBC complex inhibits mTORC1, thereby preventing phosphorylation of ribosomal protein S6 kinase (RPS6KB1 and RPS6KB2) and EIF4EBP1 (4E-BP1) . This inhibition ultimately suppresses protein translation and cellular growth. The complex is inactivated in response to nutrients, relieving inhibition of mTORC1 . TSC2 is also involved in microtubule-mediated protein transport via its ability to regulate mTORC1 signaling and can stimulate the intrinsic GTPase activity of Ras-related proteins RAP1A and RAB5 .

Experimental Applications and Methodologies

For optimal antibody performance and longevity, follow these storage and handling guidelines:

• Short-term storage (up to 2 weeks): Maintain refrigerated at 2-8°C .

• Long-term storage: Store at -20°C in small aliquots to prevent freeze-thaw cycles, which can degrade antibody activity .

• Some formulations contain 50% glycerol, 0.5% BSA, and 0.02% sodium azide as stabilizers .

• When working with the antibody, keep it on ice and return to proper storage promptly after use.

• Avoid repeated freeze-thaw cycles by preparing small working aliquots of the antibody upon receipt .

• Check the specific manufacturer's guidelines, as storage recommendations may vary slightly between suppliers.

What controls should be included when using Phospho-TSC2 (S939) Antibody in experiments?

For rigorous and reproducible research with Phospho-TSC2 (S939) Antibody, include the following controls:

• Positive control: Cell lines known to express phosphorylated TSC2 at S939, such as insulin-stimulated cells or cells with activated PI3K/Akt pathway. MCF-7 cells have been validated for this purpose .

• Negative controls:

  • Untreated cells (without stimulation that induces S939 phosphorylation)

  • Cells treated with PI3K inhibitors like wortmannin, which ablates the phosphorylation

  • Phosphatase-treated lysates to remove phosphorylation

• Specificity controls:

  • Competition assays using phosphorylated and non-phosphorylated S939 peptides to verify antibody specificity

  • TSC2 knockout or knockdown cells to confirm signal specificity

  • S939A mutant TSC2 expressing cells, which should not be recognized by the antibody

• Loading controls: Appropriate housekeeping proteins (for Western blots) or total cell staining (for cell-based assays) to normalize for variations in sample loading or cell number .

How does phosphorylation at S939 interact with other post-translational modifications of TSC2?

The function of TSC2 is regulated by a complex network of post-translational modifications. S939 phosphorylation must be considered in the context of other modifications:

• Multiple phosphorylation sites: Besides S939, TSC2 is also phosphorylated at T1462 by Akt/PKB, and both modifications appear to cooperatively regulate TSC2 function in the PI3K/Akt pathway . Research shows that while S939 phosphorylation is critical for cytosolic localization, T1462 phosphorylation does not appear to direct translocation of tuberin from the membrane to the cytosol .

• Cooperative phosphorylation: S939 and S981 phosphorylation sites contribute to cytosolic localization. Importantly, phosphorylation at S939 alone (in S981A mutants) is not sufficient to partition tuberin to the cytosol, suggesting a cooperative mechanism .

• Interaction with 14-3-3 proteins: Phosphorylated S939 and S981 serve as binding sites for 14-3-3 proteins. Competition assays demonstrate that phosphorylated S939 and S981 peptides compete for the interaction of tuberin with several 14-3-3 isoforms, while non-phosphorylated peptides do not .

• Ubiquitination: TSC2 can be ubiquitinated by the DCX(FBXW5) E3 ubiquitin-protein ligase complex and by MYCBP2, leading to its degradation. Association with TSC1 protects it from ubiquitination . Researchers should consider how phosphorylation might influence ubiquitination patterns.

What experimental approaches can resolve contradictory findings in TSC2 phosphorylation studies?

When facing contradictory results in TSC2 phosphorylation research, consider these methodological approaches:

• Temporal dynamics analysis: Use time-course experiments to track phosphorylation changes after stimulation, as contradictions may arise from different sampling timepoints.

• Cell type-specific differences: TSC2 is expressed in various tissues including liver, brain, heart, lymphocytes, fibroblasts, biliary epithelium, pancreas, skeletal muscle, kidney, lung, and placenta . Different cell types may show different phosphorylation patterns and responses, so validate findings across multiple relevant cell lines.

• Pathway cross-talk assessment: Analyze the influence of other signaling pathways that may interact with the PI3K/Akt pathway and affect TSC2 phosphorylation status. For example, the AMPK pathway phosphorylates TSC2 at different sites and activates it, leading to negative regulation of mTORC1 .

• Mutational analysis: Create phospho-mimetic (S939D/E) and phospho-dead (S939A) mutations to study the functional consequences of S939 phosphorylation in isolation from other modifications .

• Subcellular fractionation: Perform rigorous subcellular fractionation studies to accurately determine the localization changes induced by phosphorylation, as demonstrated in research showing S939A and S981A mutants predominantly localize to the membrane .

How can researchers distinguish between physiological and pathological TSC2 phosphorylation?

Distinguishing between normal physiological phosphorylation and pathological states requires sophisticated experimental designs:

• Quantitative phosphorylation analysis: Use quantitative phosphoproteomics or cell-based ELISA assays to measure the stoichiometry of S939 phosphorylation under different conditions . Compare phosphorylation levels between normal and disease models.

• Physiological stimulus gradients: Apply graded concentrations of physiological stimuli (insulin, growth factors) to determine threshold levels where TSC2 phosphorylation transitions from physiological to potentially pathological states.

• Disease model validation: Compare phosphorylation patterns in cells derived from tuberous sclerosis complex patients versus controls to identify disease-specific alterations.

• Functional correlation studies: Correlate degrees of S939 phosphorylation with downstream functional outcomes (mTORC1 activity, cell growth, autophagy suppression) to establish functionally relevant thresholds.

• In vivo verification: Validate findings from cell culture in appropriate animal models to ensure physiological relevance, especially when studying conditions like tuberous sclerosis complex where TSC2 mutations play a causative role .

What are common causes for weak or absent signal when using Phospho-TSC2 (S939) Antibody?

When encountering weak or absent signals with Phospho-TSC2 (S939) Antibody, consider these potential issues and solutions:

• Insufficient phosphorylation: TSC2 S939 phosphorylation is dynamic and stimulus-dependent. Ensure cells are properly stimulated (insulin, growth factors) before lysis. The phosphorylation may be transient, so optimize stimulation time.

• Phosphatase activity: Phosphatases can rapidly dephosphorylate proteins during sample preparation. Include phosphatase inhibitors in all buffers used during cell lysis and protein extraction.

• Antibody concentration: The recommended dilution ranges vary by application (1:500-1:2000 for WB, 1:10-1:50 for IF) . Optimize antibody concentration for your specific experimental system.

• Epitope masking: Protein-protein interactions or other post-translational modifications might mask the S939 phosphorylation site. Consider using different lysis conditions or detergents.

• Sample degradation: TSC2 is a large protein (~200 kDa) that may be vulnerable to degradation. Use fresh samples and protease inhibitors during preparation.

• Detection method sensitivity: For weakly phosphorylated samples, consider using more sensitive detection methods like chemiluminescence with signal enhancement for Western blots.

How can researchers validate the specificity of phospho-signal detected in their experiments?

To validate the specificity of the phospho-signal detected with Phospho-TSC2 (S939) Antibody:

• Phosphatase treatment control: Treat duplicate samples with lambda phosphatase to remove all phosphorylations. The signal should disappear in phosphatase-treated samples.

• Peptide competition assay: Pre-incubate the antibody with phosphorylated and non-phosphorylated S939 peptides before the experiment. The phosphorylated peptide should abolish the signal while the non-phosphorylated peptide should not affect it .

• Phospho-site mutants: Express wild-type TSC2 and S939A mutant in cells with low endogenous TSC2. The antibody should detect only the wild-type protein after appropriate stimulation.

• Pathway inhibition: Treat cells with specific inhibitors of the PI3K/Akt pathway (e.g., wortmannin, LY294002) before stimulation. This should prevent S939 phosphorylation and eliminate the signal .

• Genetic knockdown/knockout validation: Use siRNA knockdown or CRISPR/Cas9 knockout of TSC2 to confirm the specificity of the band or signal observed.

What methodological approaches can improve detection of low abundance TSC2 phosphorylation?

For improved detection of low abundance TSC2 phosphorylation at S939, researchers can employ these strategies:

• Enrichment techniques:

  • Immunoprecipitate TSC2 before Western blotting to concentrate the protein

  • Use phospho-protein enrichment columns to isolate phosphorylated proteins from cell lysates

• Signal amplification methods:

  • Employ tyramine signal amplification for immunofluorescence detection

  • Use highly sensitive chemiluminescent substrates for Western blotting

  • Consider proximity ligation assays to detect TSC2 phosphorylation in situ with greater sensitivity

• Phosphorylation enhancement:

  • Maximize pathway activation with combined stimuli (e.g., insulin plus EGF)

  • Inhibit phosphatases using okadaic acid or calyculin A during stimulation

  • Use phosphatase inhibitor cocktails optimized for serine/threonine phosphorylations

• Technical optimizations:

  • Reduce background by optimizing blocking conditions (e.g., test BSA vs. milk proteins)

  • Increase antibody incubation time (overnight at 4°C)

  • Use specialized low-background detection systems

• Alternative detection platforms:

  • Consider cell-based ELISA methods which can provide quantitative data with higher sensitivity

  • Mass spectrometry-based approaches for absolute quantification of phosphorylation stoichiometry

How can researchers utilize Phospho-TSC2 (S939) Antibody to investigate mTORC1 signaling dynamics?

To investigate mTORC1 signaling dynamics using Phospho-TSC2 (S939) Antibody:

• Time-resolved phosphorylation analysis: Perform time-course experiments after stimulation to track the temporal relationship between S939 phosphorylation and mTORC1 activation markers (phospho-S6K, phospho-4EBP1).

• Correlation with subcellular localization: Combine subcellular fractionation with phosphorylation detection to track how S939 phosphorylation affects TSC2 localization relative to mTORC1 components. Research has demonstrated that mutation of S939 prevents cytosolic translocation of tuberin from cellular membranes .

• Nutrient sensing circuits: Use Phospho-TSC2 (S939) Antibody to investigate how different nutrient conditions affect S939 phosphorylation status and correlate with mTORC1 activity, as the TSC-TBC complex is inactivated in response to nutrients, relieving inhibition of mTORC1 .

• Pathway crosstalk mapping: Systematically inhibit or activate other signaling pathways (MAPK, AMPK, etc.) and measure effects on S939 phosphorylation to map the signaling network regulating TSC2.

• Single-cell analysis: Combine with phospho-flow cytometry or quantitative immunofluorescence to analyze cell-to-cell variability in S939 phosphorylation and correlate with mTORC1 activity markers at the single-cell level.

What approaches can effectively study the interaction between phosphorylated TSC2 and 14-3-3 proteins?

To effectively study the interaction between phosphorylated TSC2 and 14-3-3 proteins:

• Co-immunoprecipitation assays: Use anti-TSC2 or anti-14-3-3 antibodies to precipitate protein complexes, then probe with Phospho-TSC2 (S939) Antibody or anti-14-3-3 antibodies to detect interactions. Research has shown that 14-3-3 can directly interact with phosphorylated tuberin .

• Peptide competition studies: Utilize phosphorylated and non-phosphorylated S939 peptides in competition assays to block GST-14-3-3 interaction with tuberin. Studies have demonstrated that phosphorylated S939 peptides compete for this interaction while non-phosphorylated peptides do not .

• Mutational analysis: Compare wild-type TSC2 with S939A mutants for 14-3-3 binding. Research has shown that the 2A mutant (S939A/S981A) dramatically reduces affinity purification by 14-3-3 compared to wild-type tuberin .

• Pathway manipulation: Treat cells with PI3K inhibitors like wortmannin, which has been shown to ablate the 14-3-3-tuberin interaction .

• Proximity-based assays: Use techniques like bimolecular fluorescence complementation (BiFC) or FRET to visualize TSC2-14-3-3 interactions in living cells and monitor how they change with cell stimulation or stress.

How can researchers investigate the role of S939 phosphorylation in tuberous sclerosis complex pathogenesis?

To investigate the role of S939 phosphorylation in tuberous sclerosis complex (TSC) pathogenesis:

• Patient-derived samples analysis: Compare S939 phosphorylation levels in cells or tissues from TSC patients versus healthy controls using Phospho-TSC2 (S939) Antibody.

• Functional impact of TSC2 mutations: Express disease-associated TSC2 mutations in cell models and analyze their effect on S939 phosphorylation and downstream mTORC1 activity.

• Genetic rescue experiments: In cells with TSC2 mutations, test whether expression of phospho-mimetic (S939D/E) or phospho-resistant (S939A) TSC2 variants can rescue normal mTORC1 regulation.

• Animal model studies: Develop knock-in mouse models with TSC2 S939A or S939D mutations to study the in vivo consequences of altered phosphorylation on development and tumor formation.

• Therapeutic targeting strategies: Use Phospho-TSC2 (S939) Antibody to monitor the efficacy of PI3K/Akt inhibitors in restoring proper TSC2 function in disease models, as mutations in TSC2 lead to tuberous sclerosis complex and the protein is believed to be a tumor suppressor .